Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022
Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 33 citations in OpenAlex.
- Bortezomib in Patients Who Fail BTKi in Waldenström Macroglobulinaemia.Hematology reports · 2026Article
- Lobar Yttrium-90 Radioembolization with BSA-Based Dosimetry for Unresectable Hepatocellular Carcinoma: Baseline Vascularity Predicts Responders to the Combination with Targeted Therapy or Immune Checkpoint Inhibition.Journal of hepatocellular carcinoma · 2025Article
- Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 2- Focus on Therapy.Mediterranean journal of hematology and infectious diseases · 2025Review
- Recent updates in the indolent lymphomas: Update on marginal zone lymphoma and Waldenström's macroglobulinemia.Hematological oncology · 2024Review
- Current approach to Waldenström macroglobulinemia.Blood reviews · 2023Review
- Advances in Treatment of Waldenström Macroglobulinemia.Current oncology reports · 2023Review
- Article
- Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.American journal of hematology · 2023Article
- Minimal residual disease status improved the response evaluation in patients with Waldenström's macroglobulinemia.Frontiers in immunology · 2023Article
- Waldenstrom Macroglobulinemia: Tailoring Therapy for the Individual.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Review
- Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care.JCO oncology practice · 2022Article
- Serum neurofilament light chain, contactin-1 and complement activation in anti-MAG IgM paraprotein-related peripheral neuropathy.Journal of neurology · 2022Article
- Monoclonal antibody-based therapies for Waldenström's macroglobulinemia.Leukemia research reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 8 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeProteasome inhibitors are effective in Waldenström's macroglobulinemia (WM) but require parenteral administration and are associated with polyneuropathy. We investigated efficacy and toxicity of the less neurotoxic oral proteasome inhibitor ixazomib combined with rituximab, in patients with relapsed WM.
methodsWe conducted a multicenter phase I/II trial with ixazomib, rituximab, and dexamethasone (IRD). Induction consisted of eight cycles IRD wherein rituximab was started in cycle 3, followed by rituximab maintenance. Phase I showed feasibility of 4 mg ixazomib. Primary end point for phase II was overall response rate (ORR [≥ minimal response]) after induction.
resultsA total of 59 patients were enrolled (median age, 69 years; range, 46-91 years). Median number of prior treatments was 2 (range, 1-7); 70% had an intermediate or high WM-IPSS (International Prognostic Scoring System for WM) score. After eight cycles, ORR was 71% (42 out of 59) (14% very good partial response [PR], 37% PR, and 20% minor response). Depth of response improved until month 12 (best ORR 85% [50 out of 59]: 15% very good PR, 46% PR, and 24% minor response). Median duration of response was 36 months. The average hematocrit level increased significantly (0.33-0.38 L/L) after induction (
conclusionCombination of IRD shows promising efficacy with manageable toxicity in patients with relapsed or refractory WM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.